Ventrus Biosciences (VTUS) Trading Near Cash Value Says Cantor Fitzgerald

November 14, 2012 9:24 AM EST Send to a Friend
Get Alerts VTUS Hot Sheet
Price: $1.45 --0%

Rating Summary:
    5 Buy, 2 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 14 | Down: 28 | New: 51
Trade VTUS Now!
Join SI Premium – FREE
Analysts at Cantor Fitzgerald continue to see value in shares of Ventrus Biosciences (NASDAQ: VTUS), though the stock has declined 75 percent this year.

"VTUS has traded down to practically cash value. At the current stock price of $2.06 and 13M shares outstanding, the market cap is approximately $26.8M, whereas the company has a cash balance of $23.6M (and will not need financing until late 2013, in our view)," said analyst Irina Rivkind.

She thinks the market is assigning minimal value to the company's Phase III asset in anal fissure, which should be market-ready by end of 2014.

"Management plans to report the results of its anal fissure market research in a few weeks, which we believe should re-energize the stock to some extent," added Rivkind.

Cantor Fitzgerald maintained a Buy on Ventrus Biosciences (NASDAQ: VTUS) with a price target of $7.00. The stock was upgraded from Hold on August 10th.

For an analyst ratings summary and ratings history on Ventrus Biosciences click here. For more ratings news on Ventrus Biosciences click here.

Shares of Ventrus Biosciences closed at $2.06 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments, Analyst EPS View

Related Entities

Cantor Fitzgerald

Add Your Comment